- Home
- IMMP vs ALDX Comparison
IMMP vs ALDX Comparison
Compare IMMP & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMP
- ALDX
- Stock Information
- Founded
- IMMP 1987
- ALDX 2004
- Country
- IMMP Australia
- ALDX United States
- Employees
- IMMP N/A
- ALDX N/A
- Industry
- IMMP Biotechnology: Pharmaceutical Preparations
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- IMMP Health Care
- ALDX Health Care
- Exchange
- IMMP Nasdaq
- ALDX Nasdaq
- Market Cap
- IMMP 211.1M
- ALDX 133.7M
- IPO Year
- IMMP N/A
- ALDX 2014
- Fundamental
- Price
- IMMP $1.86
- ALDX $2.16
- Analyst Decision
- IMMP Buy
- ALDX Strong Buy
- Analyst Count
- IMMP 2
- ALDX 2
- Target Price
- IMMP $8.50
- ALDX $9.50
- AVG Volume (30 Days)
- IMMP 648.0K
- ALDX 1.5M
- Earning Date
- IMMP 05-16-2025
- ALDX 05-20-2025
- Dividend Yield
- IMMP N/A
- ALDX N/A
- EPS Growth
- IMMP N/A
- ALDX N/A
- EPS
- IMMP N/A
- ALDX N/A
- Revenue
- IMMP $3,019,249.00
- ALDX N/A
- Revenue This Year
- IMMP $11.25
- ALDX N/A
- Revenue Next Year
- IMMP $10.22
- ALDX N/A
- P/E Ratio
- IMMP N/A
- ALDX N/A
- Revenue Growth
- IMMP 24.11
- ALDX N/A
- 52 Week Low
- IMMP $1.32
- ALDX $1.14
- 52 Week High
- IMMP $3.34
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- IMMP 53.43
- ALDX 34.82
- Support Level
- IMMP $1.44
- ALDX $1.90
- Resistance Level
- IMMP $2.71
- ALDX $2.89
- Average True Range (ATR)
- IMMP 0.17
- ALDX 0.23
- MACD
- IMMP 0.05
- ALDX 0.10
- Stochastic Oscillator
- IMMP 29.75
- ALDX 26.26
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.